Published in BMC Infect Dis on September 17, 2015
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis (2015) 0.93
Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One (2015) 0.88
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis (2016) 0.82
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis (2015) 0.76
Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet (2007) 3.73
New strategies for the elimination of polio from India. Science (2006) 3.27
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet (2010) 3.13
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis (2009) 2.05
Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science (2014) 2.00
Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog (2012) 1.50
Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria. BMC Med (2014) 1.35
Expert review on poliovirus immunity and transmission. Risk Anal (2012) 1.18
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal (2013) 1.16
Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis (2015) 1.14
Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis (2014) 1.10
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal (2013) 1.10
Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis (2014) 1.07
Successes and shortcomings of polio eradication: a transmission modeling analysis. Am J Epidemiol (2013) 1.06
Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal (2013) 1.05
Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. J Infect Dis (1995) 1.04
Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis (2014) 1.03
Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis (2015) 1.03
Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. J Infect Dis (2014) 1.01
The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis (2014) 1.01
Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis (2014) 1.01
Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal (2012) 0.97
An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis (2015) 0.96
Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal (2013) 0.90
Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One (2015) 0.88
Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine (2015) 0.85
Quantifying the impact of expanded age group campaigns for polio eradication. PLoS One (2014) 0.83
An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis (2015) 0.96
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis (2015) 0.93
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis (2015) 0.93
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis (2016) 0.82
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis (2016) 0.82